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Background and Objectives. Patients with acute
myeloblastic leukemia (AML) with features of myelodys-
plastic syndrome and abnormalities of megakaryocy-
topoiesis often have cytogenetic aberrations of 3q21 and
3q26 bands involving the paracentric inversion [inv(3)
(q21q26)] or a reciprocal translocation [t(3;3)
(q21;q26)]. These abnormalities frequently cause inap-
propriate expression of the EVI1 gene located at 3q26.
Other genes that have been implicated at the rearrange-
ment breakpoint are GR6 and RPN1 (both on 3q21). The
aim of this study was to investigate the expression of the
EVI1 fusion genes in AML patients with 3q21q26 syn-
drome. 
Design and Methods. We used reverse transcription
polymerase chain reaction to evaluate the expression of
EVI1 and GR6, and particularly of the fusion genes RPN1-
EVI1 and GR6-EVI1 in 9 AML patients with either
inv(3)(q21q26) (7 cases) or t(3;3)(q21;q26) (2 cases). 
Results. EVI1 and GR6 were always expressed, as was
RPN1-EVI1; GR6-EVI1 was absent. In 8/9 patients, the
part of EVI1 retained in RPN1-∆EVI1 contained blocks B
and C of the PR domain commonly found in the MDS1-
EVI1 gene. In the remaining patient [with inv(3)
(q21q26)], only block C was retained: we named this
variant fusion gene RPN1-∆EVI1. This patient lacked the
micromegakaryocytopoiesis frequently found in 3q21q26
syndrome. 
Interpretation and Conclusions. These findings sup-
port the hypothesis that EVI1 activation plays a dominant
role in the pathogenesis of the 3q21q26 syndrome. EVI1
expression might occur either as a consequence of
rearrangements leading to the formation of different
fusion transcripts, such as RPN1-EVI1 and RPN1-∆EVI1
or following disruption of the PR activation domain of the
MDS1-EVI1 gene.
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Specific chromosomal abnormalities involving bands3q21 and 3q26 have been observed in all FAB sub-types of acute myeloid leukemia (AML) (but in sub-
type M3 only as a second event),1,2 in myelodysplastic
syndrome (MDS),3 and in the blastic phase of chronic
myeloid leukemia (CML).4 The rearrangements of 3q
encountered in AML are the paracentric inversion inv(3)
(q21q26) and a reciprocal translocation t(3;3)(q21;q26).5
A recurrent translocation or inversion between the
regions of 3q21 and 3q26 gives rise to the so-called
3q21q26 syndrome, which is found in 0.5%–2% of adult
patients with MDS or AML.6-8 This syndrome is accom-
panied by specific, but not invariable, clinical features
including: normal or elevated platelet counts at the ini-
tial diagnosis, hyperplasia with dysplasia of megakary-
ocytes, poor response to chemotherapy, and poor prog-
nosis.9,10
The 3q26.2 chromosome band contains EVI1, which
was originally identified as a retroviral integration site
leading to myeloid tumors in susceptible strains of
mice.11,12 The EVI1 gene, which is highly conserved
through evolution, encodes a nuclear DNA-binding pro-
tein with two domains containing two sets of seven
and three repeats of Cys2Hys2 type of zinc finger motif.
During murine embryogenesis, EVI1 is expressed in
many organs13 and is involved in organogenesis.14 In
cell lines, EVI1 expression inhibits terminal myeloid dif-
ferentiation induced by granulocyte colony-stimulating
factor (G-CSF) or erythropoietin.15-17
The breakpoints of t(3;3)(q21;q26) have been mapped
approximately 10-330 kb upstream of the EVI1 gene,
while those of inv(3)(q21q26) are mainly downstream
of the EVI1 gene coding region,18 suggesting that one
or more genes involved in inappropriate EVI1 activation
are probably located at 3q21. The molecular cloning
and analysis of the breakpoint junctions has implicat-
ed the RPN115,16,19 and GR619 genes as fusion partners
of EVI1. In normal tissues, EVI1 is also found in a longer
isoform, named MDS1-EVI1, which encodes a protein
with an additional proximal extension of 188 amino
acids. This extension results from the splicing of most
of the MDS1 gene to the second exon of EVI1, which is
not translated in EVI1. The protein extension present in
MDS1-EVI1 has homology to the PR domain of several
zinc finger proteins that appear to function as negative
regulators of tumorigenesis.20 In addition to MDS1-
EVI1, other members of this protein family include
PRDI-BF1/BLIMPI (a transcription repressor of c-MYC)21
and RIZ (which binds to RB, the retinoblastoma tumor-
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suppressor protein).22-25 In general, the PR domain
contains three blocks of homology, block A, B and
C, which are conserved among the members of the
family.21 The PR domain of MDS1-EVI1 has a com-
plex genomic structure. The first block of homolo-
gy, block A, is derived from the small MDS1 gene
located about 300 kb upstream of EVI1. Blocks B
and C are encoded by exon 2 and part of exon 3 of
EVI1 upstream of the translation start site of EVI1
in exon 3. The chromosomal breakpoints at 3q26
usually disrupt the region encoding the PR domain
of MDS1-EVI1 and therefore result in a transcript
which still maintains the region encoding block B
and C but which has lost the upstream translation
start site.19,20,26
To investigate the expression of the EVI1 fusion
genes in 3q21q26 syndrome, we used reverse tran-
scription polymerase chain reaction (RT-PCR) in
nine AML patients with either inv(3)(q21q26) (7
cases) or t(3;3)(q21;q26) (2 cases). In all but one
patient EVI1 was transcribed from the RPN1 pro-
moter as an RPN1-EVI1 fusion gene containing the
first exon of RPN1 spliced in frame to EVI1 (RPN1
was spliced to exon 2 of EVI1). We discuss the role
of RPN1-EVI1, including this novel variant form, in
a cohort of cytogenetically defined patients with
abnormalities of 3q26. Despite our series of AML
patients having 1) only FAB M1 subtype, and some
of them having 2) low platelets counts and 3) not
pre-existing MDS aspects, we will refer to these
patients as affected by 3q21q26 syndrome.
Design and Methods
Patients and cytogenetic studies
Among the 416 cases of AML that have been cyto-
genetically studied at our institution, 14 (2%) dis-
played inv(3)(q21q26) or t(3;3)(q21;q26) at diagno-
sis. Morphologic assessment of AML was made
according to the French-American-British (FAB) clas-
sification.27 Here, we consider the 9 patients with
inv(3)(q21q26) (7 cases) or t(3;3)(q21;q26) (2 cases)
for whom cryopreserved bone marrow samples from
the time of diagnosis were available for molecular
studies (Table 1 and Table 2). Karyotyping and G-
Table 1. Morphologic and clinical features of patients at diagnosis.
Pts. Sex/age Hb WBC Plts % Peripheral Previous FAB Micro Dysmyelo- Dyserythro-
g/dL ×109/L ×109/L Blast Cells MDS MKC poiesis poiesis
1. F/45 9.8 59.0 304 50 NO M1 ++ − −
2. M/42 11.1 20.4 64 60 RAEB M1 ++ ++ +
3. M/42 8.6 13.3 225 19 NO M1 +++ ++ +
4. M/52 6.4 2.1 142 28 RAEB M1 +++ ++ ++
5. M/36 4.7 1.3 92 19 NO M1 + + +
6. M/53 6.5 23.4 56 90 NO M1 − − −
7. F/26 8.3 7.7 230 37 RAEB M1 +++ ++ −
8. F/43 8.3 6.2 249 26 NO M1 +++ − −
9. F/41 5.3 18.3 26 76 NO M1 +++ − −
WBC: white blood cell count; Olts: platelets; MDS: myelodysplastic syndrome; RAEB: refractory anemia with excess of blasts; Micro MKC:
micromegakaryocytes; abnormal and elevated number of mostly mononuclear megakaryocyte-megakaryoblasts, all of which show evidence of
deficit of cytoplasmic maturation and granulation (“blue-gray granulated cytoplasm”).
Table 2. Karyotype and molecular analysis of patients
at diagnosis.
Patient Karyotype
1. 46,XX,inv(3)(q21q26)  [15/15]
2. 45,XY,inv(3)(q21q26), -5,del(7)(q22q34)[22/23]
3. 45,XY,inv(3)(q21q26),-7  [17/17]
4. 45,XY,t(3;3)(q21;q26),-7  [12/14]
5. 45,XY,t(3;3)(q21;q26),-7  [21/23]
6. 45,XY,inv(3)(q21q26),-7  [52/52]
7. 45,XY,inv(3)(q21q26),-7, del(4)(p15)  [30/30]
8. 46,XX,inv(3)(q21q26)  [31/32]
9. 46,XX,inv(3)(q21q26)  [30/30]
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banding with Wright’s stain were performed after a
short-term culture (24-48 h) without stimulation, as
described elsewhere.28 Karyotypic descriptions fol-
low the recommendations of the International Sys-
tem for Human Cytogenetic Nomenclature.29
Molecular studies
Samples and RNA isolation 
Mononuclear cells from samples were obtained
by Ficoll-Hypaque density gradient centrifugation
and were stored at -80°C in guanidinium thio-
cyanate. Extraction of total RNA and its qualitative
and quantitative controls were performed as pre-
viously described.30
RT-PCR analysis 
The random primer-based RT assay was per-
formed as previously reported.31 Expression of
RPN1-EVI1, GR6-EVI1, EVI1 and GR6 was detect-
ed by PCR using previously described sets of
primers and PCR conditions.19,32,33 The HL60 cell line
was used as a negative control for the RPN1-EVI1
fusion transcript. As a positive control, we used the
cDNA of patient #1, in which the RPN1-EVI1 fusion
transcript was confirmed by sequencing.
Nucleotide sequencing
The PCR products were gel purified and cloned
into the pCR2.1 vector using a TA cloning kit (Invit-
rogen, Milan, Italy) according to the manufactur-
er’s directions. Sequencing was performed using an
Applied Biosystems (Monza, Italy) model 373A
automated DNA sequencer using dye terminator
reactions.
Computer analysis
Translation computer analysis was performed
using Translate Tool (www.expasy.ch/tools/dna.html).
The protein identity search was performed using PSI-
BLAST at NCBI (www.ncbi.nlm.nih.gov).
Results
Clinical and cytogenetic characteristics of
the patients 
The clinical and cytogenetic characteristics of
the 9 patients are summarized in Tables 1 and 2,
respectively. Leukemic cells from all patients had a
myeloid phenotype with a similar stage of matu-
ration and were classified as M1 according to the
FAB classification. Three patients (#2, 4 and 7) who
were initially diagnosed as having MDS developed
AML within 6 months. All but one (#9 in Table 1)
patient showed normal or only mildly (#2 and 6)
reduced platelet counts. All patients had inv(3) or
t(3;3). In addition, 5 patients had monosomy 7, one
had del(7) and monosomy 5, and another had del(4)
(Table 2). All patients responded poorly to chemo-
therapy. All but one failed to achieve remission
after induction chemotherapy. Patient #5 achieved
complete hematologic and cytogenetic remission
after allogeneic bone marrow transplantation from
an HLA-matched unrelated donor. The median dis-
ease-free and overall survival was 0.5 months
(range 0-18) and 16.5 months (range 6-28),
respectively.
Detection of EVI1, GR6 and RPN1-EVI1
transcripts in all 9 patients
RT-PCR analysis of all 9 cases showed two ampli-
fied fragments of 254 and 281 bases, correspond-
ing to the two previously reported splice forms of
EVI1.33 In addition, in all cases we observed a third
band which appeared as about 120 bp (shown in
Figure 1a, lanes 6 and 7).  Sequence analysis of this
third band revealed it to be an artefact, probably
due to not specific annealing of primers. GR6
expression (280 bp band in Figure 1b) was detect-
ed in all samples.  However, in contrast to the find-
ings of Pekarsky et al.,19 we were unable to detect
any type of fusion transcript between GR6 and
EVI1.19 On the other hand, RPN1-EVI1 fusion tran-
scripts were found in all 9 cases. Eight cases
showed a 324 bp amplified fragment containing
the junction between exon 1 of RPN1 and exon 2
of EVI1. This result was confirmed both by diges-
tion with the restriction endonuclease Hae III,
which yielded the expected three fragments of 192
bp, 84 bp, and 48 bp (Figure 1C), and also by
sequence analysis (data not shown).
Recognition of a novel RPN1-EVI1 fusion
transcript in one case
In one patient (#6), a fragment of 189 bp instead
of 324 bp was detected after amplification of the
RPN1-EVI1 fusion junction (Figure 1D). Sequence
analysis showed that this smaller cDNA fragment
contained the junction between nucleotide 276 of
RPN1 and nucleotide 213 of EVI1 corresponding to
the beginning of the third exon. The fusion retained
the correct reading frame. We called this fusion
transcript RPN1-∆EVI1. Interestingly, this patient,
unlike the other eight patients, did not show micro-
megakaryocytopoiesis. Computer analysis using
Translate Tool predicted a protein product of 1160
amino acids, as compared to 1205 amino acids for
RPN1-EVI1. The so-called non-coding region of
EVI1, which in the other RPN1-EVI1 junctions
included the second exon (45 in-frame codons) and
part of the third exon (18 in-frame codons), was
reduced to the 18 codons upstream of the transla-
tional start site of EVI1 in exon 3.16 The analysis of
the RPN1-∆EVI1 junction sequence suggests that
the breakpoint in EVI1 occurs within intron 2. This
EVI1 breakpoint has not been previously described
in human leukemia with EVI1 rearrangements. How-
ever, retroviral integration sites in intron 1 and 2 of
G. Martinelli et al.
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EVI1 leading to EVI1 activation and leukemia have
been reported in mice infected with an ecotropic
retrovirus.12
PSI-BLAST searches
Using the PR domain peptide sequence of EVI1 as
a query, we performed PSI-BLAST searches of the
non-redundant protein database of the NCBI. All
known PR proteins were identified. The PSI-BLAST
search showed that all the RPN1-EVI1 fusion pro-
teins maintain homology with blocks B and C of the
PR domain. Significant matches were also found
for the RPN1-∆EVI1 protein: in this case, however,
the homology was limited to block C. Figure 3
shows the alignment of the PR domain region of
the RIZ1, BLIMP1, MDS-EVI1, RPN1-EVI1 and
RPN1-∆EVI1 with the HRX, SET1 (yeast), Su(var)3-
9 (Drosophila) and ASH1 (Drosophila) proteins. 
Discussion
All nine cases of AML with abnormalities of 3q26,
which we arbitrarily refer to as patients affected by
3q21q26 syndrome, had RPN1-EVI1 fusion tran-
scripts. In addition, one of the cases also showed a
previously non-described variant form of the fusion
junction. These observations are in line with the




Figure 1. (A). Amplification of EVI1 transcript. Elec-
trophoretic separation on 2% agarose gel of the
amplification products of EVI1 transcript. Lanes 1
to 6 represent PCR products from patients’ sam-
ples, lane 7 represents the positive control
(patient #1); lanes 8 and 9 represent negative con-
trols. MWM: molecular weight marker VIII from
Boehringer Mannheim. Expected EVI1 PCR prod-
ucts of 254 bp and 281 bp are indicated on the left
side by arrows. Two MWM of 320 bp and 242 bp
are indicated. (B). Amplification of GR6 transcript.
Electrophoretic separation on 2% agarose gel of
the amplification of GR6 transcript. Lane 1 repre-
sents MWM VIII as in Figure 1A, lanes 2 to 7 rep-
resent PCR products from patients’ samples, lane
8 represents a negative control. At present, we
have no explanation for the faint band of amplifi-
cation obtained in line 5. (C). Amplification of
RPN1-EVI1 transcript. Lane 3 shows the elec-
tophoretic separation on 2% agarose gel of a 324
bp PCR product (arrow on the right side) corre-
sponding to the RPN1 (exon 1) – EVI1 (exon 2)
junction. The same product was HaeIII restriction
digested (lane 2) and the expected three frag-
ments of 192 bp, 84 bp and 48 bp were elec-
trophoretically separated (arrows on the left side).
Lanes 1 and 4 represent MWM V and VIII of
Boehringer Mannheim. (D) Amplification of RPN1-
∆EVI1 transcript. Electrophoretic separation, as in
Figure 1C, of RPN1-EVI1 transcript in patient #1
(lane 2) and RPN1-∆EVI1 transcript  in patient #6
(lane 3). The expected PCR product of 324 bp was
reduced (189 bp) in RPN1-∆EVI1 transcript, as can
be seen from the arrowed portion on the right. The
MWM, as in Figure 1C, is partially shown.
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sometimes be a consequence of: 1) inappropriate
expression of the normal EVI1 gene product; and/or
2) inappropriate expression of an EVI1 fusion gene,
such as RPN1-EVI1; and/or 3) disruption of a nor-
mal fusion transcript containing a PR domain, such
as MDS1-EVI1.
Regarding the first possibility, EVI1 is not nor-
mally detected in human hematopoietic cells.16 The
open reading frame of the gene starts in the third
exon where the first in-frame ATG codon is locat-
ed.16 The second exon can be activated by chromo-
somal rearrangements in which EVI1 is juxtaposed
to RPN1. Transcription of the RPN1-EVI1 fusion
gene starts from the RPN1 promoter. It is not cur-
rently clear whether EVI1 is also inappropriately
expressed by its own promoter. Our findings
strongly support the concept that inappropriate
EVI1 expression plays a primary role in the 3q21q26
syndrome. Indeed, all the blasts of our 9 patients
showed aberrant expression of the EVI1 transcript.
Due to the small size of the available bone marrow
samples, we were unable to perform Northern or
Western blot analysis to confirm the RT-PCR
results.
Leukemic transformation in AML or MDS as well
as in CML in blastic phase has also been associat-
ed with the inappropriate expression of EVI1 in
other fusion genes, such as TEL-MDS1-EVI1 or
AML1-MDS1-EVI1 resulting respectively from a
t(3;12)(q26;p13) or a t(3;21)(q26;q22).3,4,16 It is not
yet known whether inappropriate EVI1 expression
is sufficient for leukemic transformation or
whether the other gene partners involved in the
translocation also play a role. It has been suggest-
ed that gene rearrangements associated with the
3q21q26 syndrome must carry an element at 3q21
into the region of the EVI1 gene for EVI1 activa-
tion.12,32-34 RPN1 is a main candidate, and GR6 may
be another one.19 Even though GR6 fusion genes
have been reported to be involved in EVI1 expres-
sion,19 no GR6-EVI1 fusion gene expression was
found among our AML samples. We have no expla-
nation for this discrepancy apart from chance, and
studies on a larger number of patients, represent-
ing all subtypes and characteristics of the syn-
drome, are needed to shed light on GR6 involve-
ment.
A third oncogenetic possibility is that the
rearrangements at the 3q26 region may disrupt the
normal PR-protein MDS-EVI1, which normally
functions as a growth suppressor. This situation
would be similar to that of the PR-protein RIZ,22,24
and it was suggested that deletion of the PR
domain of RIZ leads to a shorter protein, RIZ2, that
has acquired transforming properties. A similar
mechanism has been proposed for a novel EVI1
Figure 2. Schematic representation of normal EVI1 (a) and RPN1 (b) transcripts and the 3q21-3q26-associate:
RPN1-EVI1 (c) and RPN1-∆EVI1 (d) fusion transcripts. Striped gray boxes correspond to non-coding parts of the
EVI1 transcript (exons 1 and 2 and part of exon 3). The dotted gray box represents the RPN1 portion. The pre-
dicted lengths of protein (aa, amino acid) and codon (c.) are indicated inside the boxes. The numbers on the top
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gene family, MEL1 lacking a PR domain (MEL1S)
which is mainly expressed in t(1;3)(p36;q21)-pos-
itive AML and blocks G-CSF-induced myeloid dif-
ferentiation.24 It was suggested that the PR domain
may act as a protein binding motif20,23 and it
appears to function as a negative regulator of
tumorigenesis.21-23,26 In this regard, RPN1-EVI1 may
not only cause inappropriate EVI1 expression, but
also produce EVI1 proteins lacking at least part of
the PR domain. We found that all but one of the
RPN1-EVI1 transcripts that we have detected
maintained the region of EVI1 encoding blocks B
and C of the PR domain. The remaining case (n. 6)
expressed the novel transcript junction RPN1-
∆EVI1 encoding only block C of the PR domain. Our
sequence homology search indicated that the PR
domain is maintained through evolution from yeast
to mammalian cells, and that it has remarkable
homology to proteins that are associated with
chromatin remodeling. Thus, lack or inactivation of
PR domains in a gene may lead to specific inacti-
vation of its chromatin-associated functions, with-
out affecting its other functions such as DNA bind-
ing and chromatin-independent transcriptional
activation or repression.35,36 The possible effects on
chromatin structure regulation could cause major
functional differences between products retaining
larger or smaller portions of the PR domain. Our
finding of the RPN1-∆EVI1 transcript suggests that
this concept may apply for the MDS1-EVI1 gene.
In conclusion, our findings support the hypothe-
sis that activation of EVI1 expression plays a role
in the pathogenesis of the 3q21q26 syndrome. EVI1
expression might occur either as a consequence of
rearrangements leading to the formation of a par-
ticular fusion transcript, or following disruption of
the PR activator domain of MDS1-EVI1: either of
these two possible mechanisms could change the
transcription regulatory property of EVI1 from an
activator of promoters containing the AGATA DNA
sequence to a repressor.
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